Novozymes' bioenergy division had a surprisingly poor early 2019. With DKK 623 million (EUR 83.4 million) in divisional revenue, Q1 sales retreated by 8 percent relative to the same period last year, further contributing to an aggregated net result decline of almost DKK 100 million to DKK 697 million. This fall was the primary factor behind the downgraded organic growth guidance, adjusted from 3-6 to 3-5 percent, shows the company's first quarter interim report.
"The first-quarter decline in sales was no surprise – we communicated this back in January. We also expected US bioethanol to be down, but the decline was larger than we had foreseen. The floods in the Midwest have made it tougher for our customers," writes Novozymes Chief Executive Peder Holk Nielsen in the report and continues:
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for EnergyWatch has now started
With your free trial you get:
Full access to all locked articles on EnergyWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.